Milka Malesevic

Dr. Milka Malesevic

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MIMarija Ivanov
Marija Ivanov
KNKatarina Novovic
Katarina Novovic
MMMilka Malesevic
Milka Malesevic
MDMiroslav Dinić
Miroslav Dinić
Dejan StojkovicDejan Stojkovic
Dejan Stojkovic
MSMarina Soković
Marina Soković
The rising incidence of antibiotic resistant microorganisms urges novel antimicrobials development with polyphenols as appealing potential therapeutics. We aimed to reveal the most promising polyphenols among hesperetin, hesperidin, naringenin, naringin, taxifolin, rutin, isoquercitrin, morin, chlorogenic acid, ferulic acid, p-coumaric acid, and gallic acid based on antimicrobial capacity, antibiofilm potential, and lack of cytotoxicity towards HaCaT, and to further test its antivirulence mechanisms. Although the majority of studied polyphenols were able to inhibit bacterial growth and biofilm formation, the most promising activities were observed for rutin. Further investigation proved rutin’s ability to prevent/eradicate Pseudomonas aeruginosa and MRSA urinary catheter biofilms. Besides reduction of biofilm biomass, rutin antibiofilm mechanisms included reduction of cell viability, exopolysaccharide, and extracellular DNA levels. Moderate reduction of bacterial adhesion to human keratinocytes upon treatment was observed. Rutin antivirulence mechanisms included an impact on P. aeruginosa protease, pyocyanin, rhamnolipid, and elastase production and the downregulation of the lasI, lasR, rhlI, rhlR, pqsA and mvfR genes. Rutin also interfered with membrane permeability. Polyphenols could repress antibiotic resistant bacteria. Rutin has shown wide antimicrobial and antibiofilm capacity employing a range of mechanisms that might be used for the development of novel antimicrobials.

1 December 2020 in Microbial Pathogenesis
Verified
Journal Article
Closed access
MMMilka Malesevic
Milka Malesevic
NSNemanja Stansavljevic
Nemanja Stansavljevic
KNKatarina Novovic
Katarina Novovic
NPNatalija Polovic
Natalija Polovic
ZVZorica Vasiljević
Zorica Vasiljević
BJBranko Jovcic
Branko Jovcic

25 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MOMina Obradović
Mina Obradović
MMMilka Malesevic
Milka Malesevic
MLMariagrazia Di Luca
Mariagrazia Di Luca
DKDusan Kekic
Dusan Kekic
IGIna Gajic
Ina Gajic
MKMilan Kojić
Milan Kojić
Klebsiella pneumoniae is a global health threat and bacteriophages are a potential solution in combating pandrug-resistant K. pneumoniae infections. Two lytic phages, LASTA and SJM3, active against several pandrug-resistant, nosocomial strains of K. pneumoniae were isolated and characterized. Their host range is narrow and latent period is particularly long; however, their lysogenic nature was refuted using both bioinformatic and experimental approaches. Genome sequence analysis clustered them with only two other phages into the new genus Lastavirus. Genomes of LASTA and SJM3 differ in only 13 base pairs, mainly located in tail fiber genes. Individual phages, as well as their cocktail, demonstrated significant bacterial reduction capacity in a time-dependent manner, yielding up to 4 log reduction against planktonic, and up to 2.59 log on biofilm-embedded, cells. Bacteria emerging from the contact with the phages developed resistance and achieved numbers comparable to the growth control after 24 h. The resistance to the phage seems to be of a transient nature and varies significantly between the two phages, as resistance to LASTA remained constant while resensitization to SJM3 was more prominent. Albeit with very few differences, SJM3 performed better than LASTA overall; however, more investigation is needed in order to consider them for therapeutic application.

28 February 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Open access
JCJovana Curcic
Jovana Curcic
MDMiroslav Dinic
Miroslav Dinic
KNKatarina Novovic
Katarina Novovic
ZVZorica Vasiljevic
Zorica Vasiljevic
MKMilan Kojic
Milan Kojic
MMMilka Malesevic
Milka Malesevic
Infections caused by multidrug-resistant pathogens are one of the biggest challenges facing the healthcare system today. Quorum quenching (QQ) enzymes have the potential to be used as innovative enzyme-based antivirulence therapeutics to combat infections caused by multidrug-resistant pathogens. The main objective of this research was to describe the novel YtnP lactonase derived from the clinical isolate Stenotrophomonas maltophilia and to investigate its antivirulence potential against multidrug-resistant Pseudomonas aeruginosa MMA83. YtnP lactonase, the QQ enzyme, belongs to the family of metallo-β-lactamases. The recombinant enzyme has several advantageous biotechnological properties, such as high thermostability, activity in a wide pH range, and no cytotoxic effect. High-performance liquid chromatography analysis revealed the activity of recombinant YtnP lactonase toward a wide range of N-acyl-homoserine lactones (AHLs), quorum sensing signaling molecules, with a higher preference for long-chain AHLs. Recombinant YtnP lactonase was shown to inhibit P. aeruginosa MMA83 biofilm formation, induce biofilm decomposition, and reduce extracellular virulence factors production. Moreover, the lifespan of MMA83-infected Caenorhabditis elegans was prolonged with YtnP lactonase treatment. YtnP lactonase showed synergistic inhibitory activity in combination with gentamicin and acted additively with meropenem against MMA83. The described properties make YtnP lactonase a promising therapeutic candidate for the development of next-generation antivirulence agents.

1 January 2021 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
MMMilka Malesevic
Milka Malesevic
NSNemanja Stansavljevic
Nemanja Stansavljevic
MMMarija Miljkovic
Marija Miljkovic
BJBranko Jovcic
Branko Jovcic
BFBrankica Filipić
Brankica Filipić
MKMilan Kojić
Milan Kojić

14 November 2024 in European Journal of Clinical Microbiology & Infectious Diseases
Verified
Journal Article
Closed access
PDF file
KNKatarina Novovic
Katarina Novovic
MRMilica Radovanović
Milica Radovanović
IGIna Gajic
Ina Gajic
ZVZorica Vasiljević
Zorica Vasiljević
MMMilka Malesevic
Milka Malesevic
BJBranko Jovcic
Branko Jovcic